Business Daily Media

Business Marketing

.

Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China

  • Written by ACN Newswire - Press Releases

image

TOKYO, Oct 15, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without

Read more //?#

Popular

No Sign of Slowdown in Australian Corporate IT Investment

Increased Investment in Cloud Projects at the Top of IT Priority List; Market for Talent Remains Tight  Despite the rise of inflationary pressures and a global economic slowdown, few Australian organisations are scaling back ...

Research by Poshmark, Inc. Finds Aussies Sitting on $5 Billion Worth of Post lockdown Clothes

Leading social marketplace for new and secondhand style launches in Australia to empower the nation to sell their style and convert their closets into cash   From lockdowns to working from home, 79% of Aussies increased thei...

Douugh launches Micro-Investing App

Douugh (ASX: DOU), the fintech company dedicated to helping people take control of their finances, has launched a micro-investing app built for all Australians to build long-term wealth on autopilot. Designed for wealth cre...

Virtual Office
Tomorrow Business Growth